(NASDAQ: MRNA) has become a well-known name in healthcare over the past few years thanks to its COVID-19 vaccine. This vital product has allowed it to generate billions of dollars in revenue and profit.

However, the company is focusing on growth and building out its business to be larger and much more diverse in the future, especially as the pandemic recedes. Moderna has very high hopes, but are they too good to be true?

To say Moderna has an aggressive growth plan would be an understatement. Over the next five years, the company expects to launch 15 products aimed at rare diseases, infectious diseases, and cancer. And by 2025, it projects that the number of programs that it has in phase 3 trials will double.

Continue reading

Source Fool.com